C4 Therapeutics Competitors

China Biologic Products (NASDAQ:CBPO) and C4 Therapeutics (NASDAQ:CCCC) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Institutional and Insider Ownership

34.8% of China Biologic Products shares are held by institutional investors. 2.7% of China Biologic Products shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares China Biologic Products and C4 Therapeutics' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares China Biologic Products and C4 Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

China Biologic Products has higher revenue and earnings than C4 Therapeutics.

Analyst Ratings

This is a summary of recent ratings for China Biologic Products and C4 Therapeutics, as provided by MarketBeat.com.

C4 Therapeutics has a consensus price target of $44.50, indicating a potential upside of 36.71%. Given C4 Therapeutics' higher possible upside, analysts plainly believe C4 Therapeutics is more favorable than China Biologic Products.

Summary

China Biologic Products beats C4 Therapeutics on 6 of the 8 factors compared between the two stocks.

Allogene Therapeutics (NASDAQ:ALLO) and C4 Therapeutics (NASDAQ:CCCC) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Allogene Therapeutics and C4 Therapeutics, as reported by MarketBeat.

Allogene Therapeutics currently has a consensus price target of $52.0833, suggesting a potential upside of 60.55%. C4 Therapeutics has a consensus price target of $44.50, suggesting a potential upside of 36.71%. Given Allogene Therapeutics' higher probable upside, analysts clearly believe Allogene Therapeutics is more favorable than C4 Therapeutics.

Earnings and Valuation

This table compares Allogene Therapeutics and C4 Therapeutics' revenue, earnings per share and valuation.

Profitability

This table compares Allogene Therapeutics and C4 Therapeutics' net margins, return on equity and return on assets.

Institutional & Insider Ownership

59.9% of Allogene Therapeutics shares are held by institutional investors. 31.3% of Allogene Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Allogene Therapeutics beats C4 Therapeutics on 4 of the 7 factors compared between the two stocks.

C4 Therapeutics (NASDAQ:CCCC) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Analyst Recommendations

This is a breakdown of current ratings and target prices for C4 Therapeutics and Beam Therapeutics, as reported by MarketBeat.com.

C4 Therapeutics presently has a consensus target price of $44.50, suggesting a potential upside of 36.71%. Beam Therapeutics has a consensus target price of $96.00, suggesting a potential upside of 31.18%. Given C4 Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe C4 Therapeutics is more favorable than Beam Therapeutics.

Earnings & Valuation

This table compares C4 Therapeutics and Beam Therapeutics' top-line revenue, earnings per share and valuation.

C4 Therapeutics has higher earnings, but lower revenue than Beam Therapeutics.

Profitability

This table compares C4 Therapeutics and Beam Therapeutics' net margins, return on equity and return on assets.

Institutional and Insider Ownership

49.8% of Beam Therapeutics shares are held by institutional investors. 0.7% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

C4 Therapeutics beats Beam Therapeutics on 5 of the 8 factors compared between the two stocks.

C4 Therapeutics (NASDAQ:CCCC) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Earnings & Valuation

This table compares C4 Therapeutics and Iovance Biotherapeutics' top-line revenue, earnings per share and valuation.

Institutional and Insider Ownership

94.6% of Iovance Biotherapeutics shares are held by institutional investors. 9.9% of Iovance Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares C4 Therapeutics and Iovance Biotherapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and target prices for C4 Therapeutics and Iovance Biotherapeutics, as reported by MarketBeat.com.

C4 Therapeutics presently has a consensus target price of $44.50, suggesting a potential upside of 36.71%. Iovance Biotherapeutics has a consensus target price of $50.50, suggesting a potential upside of 64.87%. Given Iovance Biotherapeutics' higher probable upside, analysts plainly believe Iovance Biotherapeutics is more favorable than C4 Therapeutics.

Summary

Iovance Biotherapeutics beats C4 Therapeutics on 4 of the 7 factors compared between the two stocks.

SpringWorks Therapeutics (NASDAQ:SWTX) and C4 Therapeutics (NASDAQ:CCCC) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation.

Analyst Ratings

This is a breakdown of recent ratings for SpringWorks Therapeutics and C4 Therapeutics, as provided by MarketBeat.

SpringWorks Therapeutics currently has a consensus price target of $95.20, suggesting a potential upside of 33.26%. C4 Therapeutics has a consensus price target of $44.50, suggesting a potential upside of 36.71%. Given C4 Therapeutics' higher possible upside, analysts plainly believe C4 Therapeutics is more favorable than SpringWorks Therapeutics.

Earnings and Valuation

This table compares SpringWorks Therapeutics and C4 Therapeutics' gross revenue, earnings per share and valuation.

Profitability

This table compares SpringWorks Therapeutics and C4 Therapeutics' net margins, return on equity and return on assets.

Institutional and Insider Ownership

76.3% of SpringWorks Therapeutics shares are owned by institutional investors. 51.2% of SpringWorks Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

C4 Therapeutics (NASDAQ:CCCC) and NanoString Technologies (NASDAQ:NSTG) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations for C4 Therapeutics and NanoString Technologies, as provided by MarketBeat.

C4 Therapeutics currently has a consensus price target of $44.50, suggesting a potential upside of 36.71%. NanoString Technologies has a consensus price target of $68.60, suggesting a potential downside of 6.04%. Given C4 Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe C4 Therapeutics is more favorable than NanoString Technologies.

Earnings and Valuation

This table compares C4 Therapeutics and NanoString Technologies' top-line revenue, earnings per share and valuation.

C4 Therapeutics has higher earnings, but lower revenue than NanoString Technologies.

Profitability

This table compares C4 Therapeutics and NanoString Technologies' net margins, return on equity and return on assets.

Insider & Institutional Ownership

98.3% of NanoString Technologies shares are held by institutional investors. 4.2% of NanoString Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

C4 Therapeutics beats NanoString Technologies on 5 of the 9 factors compared between the two stocks.